Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH
Alternative Names: Alxoid; Clustek; Cluster-allergoid - ROXALL Medizin GmbH; CLUSTOID; CLUSTOID® Wiesenlieschgras; CLUSTOID® Timothy; CLUSTOID® Phleum pretense; Glutaraldehyde polymerised allergen extract - ROXALL Medizin GmbH; RoxoidLatest Information Update: 03 Mar 2023
Price :
$50 *
At a glance
- Originator Inmunotek
- Developer Inmunotek; ROXALL Medizin GmbH
- Class Allergens; Allergy immunotherapies; Antiallergics; Vaccines
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic rhinitis
- Phase II/III Rhinoconjunctivitis
Most Recent Events
- 27 Feb 2023 Phase-II/III clinical trials in Rhinoconjunctivitis (In adults) in Germany (SC) (EudraCT2022-001610-19)
- 27 Feb 2023 ROXALL Medizin initiates a phase-II/III clinical trial in Allergic rhinitis (In adults) in Germany (SC) (EudraCT2022-001610-19)
- 15 Nov 2022 ROXALL Medizin initiates the phase II/III CLUSTOID Grass Study in Allergic rhinitis in Germany (SC) (EudraCT2021-006533-19)